Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare

The divestment is a part of Fortis' ongoing portfolio rationalization strategy

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex

Merck to acquire Caraway Therapeutics

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases

Fosun Pharma USA and Treehill Partners to invest in biopharma space

The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Truqap plus Faslodex approved in the US for patients with advanced HR-positive breast cancer

First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients

Oceanic-AF study stopped early due to lack of efficacy

OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program

AskBio announces first patient randomized in Phase 1 Trial of AB-1005

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels

Alkem healthy lungs initiative to promote importance of inhalation therapy

The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases

IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ